Health AI Central
Share:
Peer-Reviewed Publication
Magn Reson Med2024;92(4):1698-1713.October 1, 2024Journal Article

A pharmacokinetic model for hyperpolarized 13C-pyruvate MRI when using metabolite-specific bSSFP sequences.

Sule Sahin1,2, Marie Frederikke Garnæs3, Anna Bennett2, Nicholas Dwork4, Shuyu Tang5, Xiaoxi Liu2, Manushka Vaidya2, Zhen Jane Wang2, Peder E Z Larson1,2
1UC Berkeley-UCSF Graduate Program in Bioengineering, University of California, Berkeley and University of California, San Francisco, California, USA.
2Radiology and Biomedical Imaging, University of California, San Francisco, California, USA.
3Department of Health Technology, Technical University of Denmark, Kongens Lyngby, Denmark.
4Biomedical Informatics and Radiology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
5Vista.ai, Palo Alto, California, USA.
PubMed PMC DOI PDF

Abstract

PURPOSE: Metabolite-specific balanced SSFP (MS-bSSFP) sequences are increasingly used in hyperpolarized [1-13C]Pyruvate (HP 13C) MRI studies as they improve SNR by refocusing the magnetization each TR. Currently, pharmacokinetic models used to fit conversion rate constants, kPL and kPB, and rate constant maps do not account for differences in the signal evolution of MS-bSSFP acquisitions. METHODS…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.